This article is more than 5 years old. Information may no longer be current.
New MICS intraocular lens performs well in a multicenter study
AMSTERDAM — Micro-incision cataract surgery with implantation of the Incise IOL produced good, stable refractive outcomes with low deviation from target refraction, according to a study.
The Incise IOL (Bausch + Lomb) is made of hydrophilic acrylic material with a 22% water content. It is an aberration-free aspheric design with a 6mm optic and a power range from 0D to 30D in 0.5D increments. The 360° sharp posterior optic edge has been optimized for effective posterior capsule opacification (PCO) prevention.
“The dedicated Viscoject injector is intended for sub-2mm incision. You can inject the IOL though a 1.4mm incision, the smallest incision currently possible,” Burkhard Dick, MD, said at the European Society of Cataract and Refractive Surgeons meeting here.
Burkhard Dick
Once in the eye, the IOL unfolds in a slow, controlled manner, he said.
Dick reported the 6-month results of a clinical study currently ongoing in 5 European sites. Biaxial (B-MICS) or micro coaxial (C-MICS) phacoemulsification procedures were equally performed using the Stellaris platform. the Viscoject inserter was used for either 1.8mm in the bag and 1.4mm wound-assist implantation.
“In the 70 eyes that have completed a 6-month follow-up, mean UCVA was 20/25 and mean BCVA was 20/20. Refractive outcomes were very good and stable, with a low deviation within 1D from target refraction,” Dick said.
No PCO was observed after 6 months, but long term results over the 2 years of the study will say more about the effectiveness of the sharp edge barrier effect of this lens.
Diclosure: Dick is a consultant to Bausch+Lomb.